ESTRO 2024 - Abstract Book

S1404

Clinical - Head & neck

ESTRO 2024

Conclusion:

Our findings represent real-life data obtained through application of a uniform, nationwide treatment strategy consisting of primary RT with radiobiological intensifications, in a national cohort of more than 3400 OPSCC patients. We observe acceptable outcomes in the overall cohort and confirm the favorable prognosis for patients with p16-positive disease. Importantly, the use of concurrent chemotherapy, hypoxic modification and accelerated fractionation all independently contributed to better LRC-rates and DFS-probabilities of the patients. This underscores the need for a careful approach at efforts to de-intensifying treatment for OPSCC, as such strategies entail the risk of compromising outcome for the patients.